临床实验研究发现，肿瘤组织中雌、孕激素受体含量的测定不仅对乳腺癌、子宫内膜癌、卵巢癌以及前列腺癌等性靶器官肿瘤的内分泌治疗有指导意义并能估测预后，在非性腺靶器官中也有一定的作用。非靶器官肿瘤组织中含有雌、孕激素受体可能有助于选择内分泌治疗及判断预后，但目前研究结果仍有矛盾。雌、孕激素受体对非性腺靶器官肿瘤的临床意义尚需进一步研讨。 Clinical trials have found that the determination of estrogen and progesterone receptors in tumor tissues not only guides endocrine therapy of breast cancer, endometrial cancer, ovarian cancer, and prostate cancer, but also can estimate prognosis. Non-gonadal target organs also have a role. Non-target organ tumors containing estrogen and progesterone receptors may help in the selection of endocrine therapy and prognosis, but the results of the current study are still contradictory. The clinical significance of estrogen and progesterone receptors for non-gonadal target organ tumors needs further study.